Oral Islatravir in Macaques Decreases Lymphocytes and Monocytes and Is Associated with Immune Alterations
Pharmaceutics · 20.03.2026 · 18 (3) · 381
DOI: 10.3390/pharmaceutics18030381 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 20.03.2026. Verfasst von Michele B Daly und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Branch, Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prev…. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CDC HHS, Centers for Disease Control and Prevention.
Abstract (Originalsprache)
Background
Islatravir (ISL) is a first-in-class nucleoside reverse transcriptase translocation inhibitor with high potency and long half-life in peripheral blood mononuclear cells (PBMCs). However, treatment and prevention of HIV with oral ISL in humans has been associated with decreases in total lymphocytes, CD4 T-cells, and B-cells in a dose-dependent manner. We investigated in macaques the effects of oral ISL on lymphocytes, monocytes, granulocytes, and gene expression in PBMCs.
Methods
Female pig-tailed macaques (n = 5) received an HIV pre-exposure prophylaxis dose of oral ISL adjusted allometrically once a week for 12 weeks. Complete blood counts and B- and T-cells were monitored prior to, during, and after ISL treatment, and changes in counts were evaluated by using a repeated measures model. Changes in gene expression were investigated in PBMCs during treatment and following treatment discontinuation.
Results
ISL treatment was associated with declines in lymphocytes (11.9%, p = 0.0015) and monocytes (22.4%, p = 0.0003), but not granulocytes (0.3%, p = 0.9781). Total lymphocytes and monocytes returned to pre-treatment levels 6 weeks after treatment cessation (p = 0.8244 and p = 0.4620, respectively). Lymphocyte subpopulation analyses showed a significant decline in CD8 (−18.4%, p = 0.0364) and CD20 (−35.3%; p = 0.0002) cells but not CD4 cells (−7.4%; p = 0.3470). Gene set enrichment analysis showed negative enrichment (padj < 0.05) of gene pathways associated with immune regulation, cell proliferation, and inflammation.
Conclusions
ISL treatment resulted in significant reductions in lymphocytes reproducing clinical toxicity. This effect was reversed after treatment cessation as observed in humans. Our results highlight the value of the macaque model to study immune alterations at the preclinical stage.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory Branch, Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
- Quantitative Sciences Branch, Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
ORCID-Profile: Michele B Daly, Daniel Kim, Seidu Inusah, J Gerardo García-Lerma
Förderung
- CDC HHS
- Centers for Disease Control and Prevention
Zitieren
APA
Daly, M. B., Kim, D., Inusah, S., Little, D., Kim, J. S., Makarova, N., Edwards, T. E., Mitchell, J., Heneine, W., Pan, Y., Dobard, C. W., & García-Lerma, J. G. (2026). Oral Islatravir in Macaques Decreases Lymphocytes and Monocytes and Is Associated with Immune Alterations. Pharmaceutics, 18(3), 381. https://doi.org/10.3390/pharmaceutics18030381
Vancouver
Daly MB, Kim D, Inusah S, Little D, Kim JS, Makarova N, et al. Oral Islatravir in Macaques Decreases Lymphocytes and Monocytes and Is Associated with Immune Alterations. Pharmaceutics. 2026;18(3):381. doi:10.3390/pharmaceutics18030381
BibTeX
@article{Daly2026,
author = {Daly, Michele B and Kim, Daniel and Inusah, Seidu and Little, Dawn and Kim, Jiyoung S and Makarova, Natalia and Edwards, Tiancheng E and Mitchell, James and Heneine, Walid and Pan, Yi and Dobard, Charles W and García-Lerma, J Gerardo},
title = {Oral Islatravir in Macaques Decreases Lymphocytes and Monocytes and Is Associated with Immune Alterations},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {3},
pages = {381},
doi = {10.3390/pharmaceutics18030381}
}
EUVIMED